Frederick R. Appelbaum
M.D., Tufts University, 1972.
A.B. (cum laude), Dartmouth College, 1968.
Our group is interested in developing an improved understanding of the biology of acute myeloid leukemia (AML) and using this knowledge to create novel therapeutic approaches. The following are several examples of such studies: (1) In one group of studies, we had previously shown that higher dose total body irradiation given in conjunction with hematopoietic cell transplantation was able to more reliably eradicate AML, but was associated with increased transplant-related toxicities. We have since shown the feasibility of targeting radiation therapy specifically to sites of normal and abnormal hematopoiesis using monoclonal antibodies against CD45 radiolabeled with 131I, and phase II trials incorporating this approach in transplant preparative regimens have yielded encouraging results. Current studies are aimed at further improving the specificity of targeting radiotherapy and defining the optimal way to apply this technique. (2) In a second group of experiments, we found that following exposure to cell-damaging agents, AML cells dramatically increase cellular cholesterol content and that blocking this response specifically sensitizes cells to chemotherapy. Subsequent clinical trials have demonstrated the feasibility of adding high dose pravastatin to leukemia induction therapy with encouraging clinical outcomes. We are currently attempting to conclusively define the role of cholesterol synthesis blockade in AML treatment. (3) In collaboration with the Southwest Oncology group, we have found that MDR1 mediated drug efflux in AML is increased in older patients and in patients with recurrent disease, and is tightly associated with drug resistance. We have completed studies showing an advantage of the use of MDR1 inhibition in patients with recurrent AML and are currently conducting clinical trials in the up-front treatment of older patients. In addition, we have identified novel compounds that inhibit not only drug efflux but the effects of BCL-2 overexpression and are attempting to define the optimal way in which to apply such therapy.
Banker, D.E., Mayer, S.J., Li, H.Y., Willman, C.L., Appelbaum, F.R., Zager, R.A. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104: 1816-1824, 2004.
Appelbaum,F.R., Gundacker,H., Head,D.R., Slovak,M.L., Willman,C.L., Godwin,J.E., Anderson,J.E., Petersdorf,S.H. Age and acute myeloid leukemia. Blood 107:3481-3485, 2006.
Larson,R.A., Sievers,E.L., Stadtmauer,E.A., Lowenberg,B., Estey,E.H., Dombret,H., Theobald,M., Voliotis,D., Bennett,J.M., Richie,M., Leopold,L.H., Berger,M.S., Sherman,M.L., Loken,M.R., van Dongen,J.J.M., Bernstein,I.D., Appelbaum,F.R. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442-1452, 2005.
Pagel,J.M., Appelbaum,F.R., Eary,J.F., Rajendran,J., Fisher,D.R., Gooley,T., Ruffner,K., Nemecek,E., Sickle,E., Durack,L., Carreras,J., Horowitz,M.M., Press,O.W., Gopal,A.K., Martin,P.J., Bernstein,I.D., Matthews,D.C. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107: 2184-2191, 2006.
Walter,R.B., Pirga,J.L., Cronk,M.R., Mayer,S., Appelbaum,F.R., Banker,D.E. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 106: 3584-3593, 2005.
In addition to overseeing a laboratory focused on the biology of acute myeloid leukemia and chairing the Leukemia Committee of the Southwest Oncology Group, Dr. Appelbaum is the head of the Program in Clinical Transplant Research at the Fred Hutchinson Cancer Research Center. The overall goal of the Program in Clinical Transplant Research is to improve the therapy of cancer in children and adults through the conduct of clinical trials, many of which involve marrow and stem cell transplantation. Major topics of these trials include the eradication of malignancy, control of graft-vs-host disease, and prevention of transplant related complications.
Alpha Omega Alpha
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Hematology
International Society for Experimental Hematology
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(4):440-7.. 2013.
Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transpl. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(26):3194-201.. 2012.
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).. Medical oncology (Northwood, London, England). 29(3):2095-101.. 2012.
Pursuing the goal of a donor for everyone in need.. The New England journal of medicine. 367(16):1555-6.. 2012.
To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision.. Clinical advances in hematology & oncology : H&O. 10(10):655-62.. 2012.
Retrospective. E. Donnall Thomas (1920-2012).. Science (New York, N.Y.). 338(6111):1163.. 2012.
Gemtuzumab ozogamicin: time to resurrect? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(32):3921-3.. 2012.
Impact of residual normal metaphases in core binding factor acute myeloid leukemia.. Cancer. 118(9):2420-2423.. 2012.
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.. 2012.
The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.. 2012.
A disease risk index for patients undergoing allogeneic stem cell transplantation.. Blood. 120(4):905-13.. 2012.
Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.. Bone marrow transplantation.. 2012.
Success of allogeneic marrow transplantation for children with severe aplastic anaemia.. British journal of haematology. 158(1):120-8.. 2012.
Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2012.
Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1 Suppl):S111-5.. 2012.